Where is ENDOless headquartered?

ENDOless is headquartered in Paris, France. The company has a team of 1-10 people.

When was ENDOless founded?

ENDOless was founded in 2024. It is based in Paris, France.

Who is the CEO of ENDOless?

Alexandra Mont is the CEO of ENDOless. The company was founded in 2024.

Where is ENDOless located?

ENDOless is headquartered in Paris, France.

What products does ENDOless offer?

ENDOless's key products include: ENDOless Mobile Application.

What funding stage is ENDOless at?

ENDOless is currently at the Early Stage stage.

How many employees does ENDOless have?

ENDOless has approximately 1-10 employees.

ENDOless

Category: AI in Healthcare

AI-powered data infrastructure and app for women with chronic gynecological conditions (starting with endometriosis; expanding to PCOS, PMS, chronic pelvic pain) — symptom tracking, predictive insights, and research-grade real-world evidence. ENDOless was founded in 2024. The company is led by Alexandra Mont. Based in Paris, France. Team size: 1-10. Total funding raised: Approximately $236K total (PitchBook), including Seed round ~$174K closed 15-Jun-2026. Earlier reported grants include €75k Women TechEU (EC). Lazio Innova grant not corroborated by public sources. Previously announced €2M seed target (May 2025).. Latest round: Pre-Seed / Grant. Key investors include WILCO, Bpifrance, Campus Founders, Incubateur Telecom Paris, European Commission (Women TechEU).

Founded: 2024
Headquarters: Paris, France
Team size: 1-10
Total funding: Approximately $236K total (PitchBook), including Seed round ~$174K closed 15-Jun-2026. Earlier reported grants include €75k Women TechEU (EC). Lazio Innova grant not corroborated by public sources. Previously announced €2M seed target (May 2025).

Value proposition

To empower women with endometriosis to take control of their condition through AI-powered predictions and personalized insights, helping them to thrive rather than just survive.

Products and solutions

ENDOless Mobile Application

Unique value

ENDOless uniquely combines symptom tracking with AI-driven predictive insights to help users anticipate and manage endometriosis flare-ups. It also aims to build a community and contribute to research, turning individual pain points into collective power.

Target customer

Women with chronic gynecological conditions (endometriosis, PCOS, PMS, chronic pelvic pain); also employers (workforce wellbeing) and researchers/pharma seeking real-world evidence.

Industries served

Healthcare, FemTech, Digital Health

Technology advantage

The core technological advantage lies in its proprietary AI algorithms that analyze user data to provide personalized and predictive health management. The business advantage is its focus on a historically underserved and poorly understood chronic condition, creating a strong, engaged user base.

How they differentiate

ENDOless differentiates itself by offering a comprehensive digital platform that connects patients and clinicians. The platform includes a symptom-tracking app for patients and a dashboard for doctors, aiming to create a multidisciplinary and personalized therapeutic path. It uses AI to correlate symptoms, habits, and therapies to predict pain onset, moving beyond simple tracking or diagnostics to offer a full-cycle management solution.

Main competitors

Endometrix, Ziwig, Demetria

Key partnerships

WILCO One E-Health (S2 2025 cohort), HIIT program — La French Tech Grand Paris + Digital Medical Hub (AP-HP), Campus Founders (Germany), France Digitale (2026 AI startups mapping)

Notable customers

Not publicly available. The company is in its early stages and has not announced any notable customers or case studies.

Major milestones

Selected for Women TechEU (European Commission) — reported grant €75k., Selected as impactful innovation at ChangeNOW 2025; opened seed raise targeting €2M (May 2025)., Featured in France Digitale 2026 Mapping of French AI Startups (Feb 2026)., Won Prix de l'Entrepreneuriat au Féminin at Made in 92 demi-finale (Jan 2026)., Selected for HIIT 2026 (La French Tech Grand Paris + Digital Medical Hub AP-HP), 24 of 70+ applicants (Mar 2026)., Participant in WILCO One E-Health S2 2025 (cohort results Apr 2026)., Exhibited with French Girls & Tech delegation at CES 2026 (Jan 2026)., Top 10 of 1,500+ for RAISE the STAKES 2026 (RAISE Summit); pitch at Carrousel du Louvre (Jun 2026)., Seed round ~$174K closed 15-Jun-2026 (PitchBook); total raised ~$236K., Campus Founders Demo Day (Germany, mid-2026).

Growth metrics

Not publicly available. As an early-stage startup, ENDOless has not yet disclosed any public growth metrics.

Market positioning

ENDOless is positioned as a deeptech women's health platform for the management of chronic gynecological conditions, with an initial focus on endometriosis. It aims to be a holistic solution for disease management rather than just a diagnostic or symptom tracking tool.

Geographic focus

The company is based in Paris, France, and its primary competitive focus appears to be on the European market.

Patents and IP

Information not publicly available.

About Alexandra Mont

Over 10 years in digital strategy, transformation consulting, and product leadership. Former Marketing Project Manager at L'Oréal; SKEMA Business School alumna (2021); PMP-certified. Founded ENDOless after a 16-year personal diagnostic delay for endometriosis.

More AI in Healthcare companies

Official website: https://www.endoless.app/